Avidity Biosciences
RNA
$24.36
Share price
2.22%
Change (1 day)
67.42%
Change (1 year)
Categories
Avidity Biosciences (RNA) - Cash on Hand
Cash on Hand as of December 2023 : $0.59 B
According to Avidity Biosciences's latest financial reports the company has $0.59 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Avidity Biosciences - Cash on Hand chart (from 2019 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.59 B | -2.52% |
| 2022-12-31 | $0.61 B | 50.59% |
| 2021-12-31 | $0.40 B | 23.59% |
| 2020-12-31 | $0.32 B | 246.95% |
| 2019-12-31 | $94.57 M | 2960.78% |
| 2018-12-31 | $3.09 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 2,031.52% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $6.35 B | 967.41% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.67 B | 181.56% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $0.87 B | 47.26% | 🇺🇸 USA |
 Fate Therapeutics
FATE | $0.31 B | -47.06% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $32.46 M | -94.55% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | $0.13 B | -76.88% | 🇺🇸 USA |